Blake Wilson is a Partner in Hogan Lovells’ FDA Regulatory group. He holds a juris doctorate from the University of Pennsylvania and a master’s degree in biostatistics from Columbia University. Prior to becoming an attorney he managed Phase I and II pharmaceutical trials at Brown University. His legal practice focuses on FDA’s premarket approval process for drugs/biologics/devices, oversight of clinical trials including BIMO audits, as well as navigating changes in laws or regulations that govern the life sciences industry. He also guides sponsors through the special designation programs available at the premarket stage, like RMAT, accelerated approval, and breakthrough. In this capacity, Blake advises extensively on novel products, study design considerations, and the use of clinical data in FDA-related matters. By stress testing clinical materials through the lens of an FDA reviewer, Blake helps sponsors avoid pitfalls that can delay or derail a project.
